EICHORCondition: Psoriatic Arthritis · Sponsor: AbbVie
Interested? Contact the study team ↓
Psoriatic arthritis (PsA) is a type of arthritis (swelling and stiffness in the joints) that is frequently seen in trial participants who also have the skin condition psoriasis. It is caused by an overactive immune system where the body attacks healthy tissue by mistake. This study aims to describe the long term usage and effectiveness with risankizumab (RZB) relative to other advanced therapeutic options for the management of PsA in daily clinical practice. Risankizumab is an approved drug for the treatment of psoriatic arthritis. The study will not be conducted in the United States, however it will be conducted in approximately 15 countries and include at least 900 and up to 1200 participants with a 2 to1 ratio of participant allocation between participants receiving risankizumab and participants receiving other advanced therapeutic agents. The therapy is prescribed in the usual manner in accordance with the terms of the local marketing authorization and professional and reimbursement guidelines with regards to dose, population, and indication. All study visits will occur during routine clinical practice and participants will be followed for 24 months. There is expected to be no additional burden for participants in this study.
This description comes directly from the study's public registry record.
Shari Chapman · 844-663-3742 · shari.chapman@abbvie.com
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Participant with a clinical diagnosis of psoriatic arthritis (PsA) with symptom onset at least 6 months prior to the Screening visit and fulfillment of ClASsification for Psoriatic ARthritis (CASPAR) at Baseline visit to confirm that the participant has active disease. * Participant must have demonstrated an inadequate response to at least 1 Disease-modifying antirheumatic drug (DMARD) (with max 50% Biologic DMARD-Inadequate Response); alternatively, participant must have demonstrated an intolerance to or contraindication for csDMARDs as determined by the investigator. Exclusion Criteria: \- Participants demonstrated an inadequate response to three or more bDMARDs/targeted synthetic DMARDs (tsDMARDs).
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Cer Instituto Médico /ID# 274445 | Quilmes, Buenos Aires, Argentina | Recruiting |
| Instituto Medico de Alta Complejidad San Isidro S.A. /ID# 274417 | San Isidro, Buenos Aires, Argentina | Recruiting |
| Instituto Médico Río Cuarto /ID# 274421 | Río Cuarto, Córdoba Province, Argentina | Recruiting |
| Landesklinikum Stockerau /ID# 275618 | Stockerau, Lower Austria, Austria | Recruiting |
| Rheuma-Zentrum Wien-Oberlaa GmbH /ID# 275617 | Vienna, State of Vienna, Austria | Recruiting |
| Medizinische Universitaet Graz /ID# 273765 | Graz, Styria, Austria | Recruiting |
| Krankenhaus Der Barmherzigen Brueder Graz /ID# 273764 | Graz, Styria, Austria | Recruiting |
| Universite Libre de Bruxelles - Hopital Erasme /ID# 272763 | Anderlecht, Brussels Capital, Belgium | Recruiting |
| Rhumaconsult Sprl /ID# 272797 | Charleroi, Hainaut, Belgium | Recruiting |
| Reumacentrum Genk - Medisch Centrum Genk /ID# 272796 | Genk, Limburg, Belgium | Recruiting |
| ReumaClinic /ID# 272782 | Genk, Limburg, Belgium | Recruiting |
| OLV Ziekenhuis Aalst /ID# 274456 | Aalst, Oost-Vlaanderen, Belgium | Recruiting |
+ 120 more locations — full list on the registry record.
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06764693